financetom
Business
financetom
/
Business
/
Cornish Metals Up 5.5% in Early Afternoon UK Trade After Updating on South Crofty Tin Project
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cornish Metals Up 5.5% in Early Afternoon UK Trade After Updating on South Crofty Tin Project
Apr 16, 2024 5:14 AM

07:58 AM EDT, 04/16/2024 (MT Newswires) -- Cornish Metals ( SBWFF ) (CUSN.V, CUSN.L) was at last look up 5.5% in early afternoon UK trade on Tuesday after it provided an update on its 100% owned South Crofty tin project located in Cornwall, United Kingdom.

The shares rose 8% yesterday in Canada.

The company said the South Crofty Preliminary Economic Assessment is "on track" for completion this quarter; and refurbishment of New Cook's Kitchen shaft is "progressing as planned" with the two winders and cages now installed, fully commissioned and certified to allow for the safe transport of equipment and workers within the shaft.

Mine dewatering continues with submersible pumps and the water treatment plant is operating correctly, with the treated water being discharged to the Red River "continues to exceed" the standards permitted by the Environment Agency, Cornish said.

"The timing of this important work coincides with a strengthening tin price, which reached over US$30,000 per tonne this past week, and an emerging recognition of tin as a critical metal by the United Kingdom and other national governments," said interim CEO Ken Armstrong. "Combined with the fact that there is presently no primary tin production in Europe or North America, these factors strongly support our thesis to fast-track work to, if feasible, responsibly bring the South Crofty tin mine back into production to the benefit of Cornwall, the United Kingdom and other stakeholders."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rite Aid to operate as private company as it emerges from Chapter 11 bankruptcy
Rite Aid to operate as private company as it emerges from Chapter 11 bankruptcy
Sep 3, 2024
(Reuters) -Rite Aid will operate as a private company as it has successfully completed its financial restructuring and emerged from Chapter 11 bankruptcy, the U.S. drugstore chain said on Tuesday. The pharmacy has used its bankruptcy to close hundreds of stores, sell its pharmacy benefit company Elixir, and negotiate settlements with its lenders, drug distribution partner McKesson and other creditors....
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Sep 3, 2024
On Tuesday, Dyne Therapeutics Inc. ( DYN ) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. This assessment of the DELIVER trial evaluating DYNE-251 includes 6-month biomarker and functional data from 8 male patients enrolled in the 20 mg/kg (approximate PMO dose) cohort...
Dyne Therapeutics Duchenne Muscular Dystrophy Drug Study Shows Improvements -- Shares Tumble
Dyne Therapeutics Duchenne Muscular Dystrophy Drug Study Shows Improvements -- Shares Tumble
Sep 3, 2024
12:30 PM EDT, 09/03/2024 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Tuesday new data from a phase 1/2 trial of DYNE-251 in patients with duchenne muscular dystrophy showed unprecedented dystrophin expression and functional improvement in multiple cohorts. The company also said the drug candidate demonstrated a favorable safety profile with treatment emergent adverse events mostly mild or moderate....
BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment
BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment
Sep 3, 2024
12:40 PM EDT, 09/03/2024 (MT Newswires) -- BioVie ( BIVI ) said Tuesday the US Food and Drug Administration has authorized its investigational new drug application to evaluate bezisterim for treating neurological symptoms associated with long COVID. The approval allows BioVie ( BIVI ) to proceed with a phase 2 trial and positions the company to receive an additional $12.6...
Copyright 2023-2026 - www.financetom.com All Rights Reserved